• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to secondary sidebar

Chronic Fatigue Syndrome

Chronic Fatigue Syndrome, Fibromyalgia, and IC Disease

  • Home
  • Fibromyalgia
    • Fibromyalgia Awareness
    • Fibromyalgia Research
    • Fibromyalgia Symptoms
    • Fibromyalgia Treatments
  • Chronic Fatigue
    • Awareness
    • Pediatric CFS
    • Research
    • Symptoms
    • Treatments
  • Chronic Illnesses
    • Cancer
    • Interstitial Cystitis
    • Irritable Bowel Syndrome
    • Chronic Pain
    • Vitamin D Deficiency
    • Women’s Health
  • Sandy’s Journey
  • Coping Corner
    • Disability
  • Articles
  • Resources
You are here: Home / ME/CFS / Treatments / FDA Requires Additional Labeling for Over-the-Counter Pain Relievers & Fever Reducers

FDA Requires Additional Labeling for Over-the-Counter Pain Relievers & Fever Reducers

Leave a Comment

For immediate release by FDA News

FDA Requires Additional Labeling for Over-the-Counter Pain Relievers and Fever Reducers to Help Consumers Use Products Safely

The Food and Drug Administration issued a final rule today that requires manufacturers of over-the-counter (OTC) pain relievers and fever reducers to revise their labeling to include warnings about potential safety risks, such as internal bleeding and liver damage, associated with the use of these popular drugs.

Products covered by the FDA action include acetaminophen, and a class of drugs known as the nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs include aspirin, ibuprofen, naproxen, and ketoprofen. Acetaminophen is in a class by itself. The revised labeling applies to all OTC pain relievers and fever reducers, including those that contain one of these ingredients in combination with other ingredients, such as in cold medicines containing pain relievers or fever reducers.

“Acetaminophen and NSAIDs are commonly used drugs for both children and adults because they are effective in reducing fevers and relieving minor aches and pain, such as headaches and muscle aches, “ said Charles Ganley, M.D., director, FDA’s Office of Nonprescription Drugs in the Center for Drug Evaluation and Research. “However, the risks associated with their use, need to be clearly identified on the label so that consumers taking these drugs are fully aware of the potential harm they can cause. It is important that they know how to take these medications safely to reduce their risk.”

Under the final rule, manufacturers must ensure that the active ingredients of these drugs are prominently displayed on the drug labels on both the packages and bottles. The labeling also must warn of the risks of stomach bleeding for NSAIDs and severe liver damage for acetaminophen.

Since 2006, some manufacturers have voluntarily revised their product labeling to identify these potential safety concerns. However, the voluntary changes to labeling do not address all of the labeling requirements in the new rule. For example, the new rule includes a warning on products containing acetaminophen that instructs consumers to ask a doctor before they are taking the blood thinning drug warfarin. The new rule requires all manufacturers to relabel their products within one year of today’s date.

Safety data reported in medical literature indicate that people sometimes take more acetaminophen than the labeling recommends. Others unknowingly take multiple products containing acetaminophen at the same time. Exceeding the recommended dosage of acetaminophen may increase the risks for severe liver damage. Alcohol use can also increase the risk of liver damage with acetaminophen.

The risk for stomach bleeding may increase in people who use NSAIDs and who are taking blood-thinning drugs (anticoagulants) or steroids. Stomach bleeding risks also increase for people who take multiple NSAIDs at the same time, or in people who take them longer than directed. Alcohol use can increase the risk for stomach bleeding with NSAIDs use.

An FDA Advisory Committee meeting will be convened on June 29 & 30, 2009, to discuss further steps the FDA could take to reduce the risk of liver damage associated with acetaminophen overdoses.

Source:  http://www.fda.gov/bbs/topics/NEWS/2009/NEW02004.html

Filed Under: Treatments Tagged With: FDA, fever reducers, pain relievers

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Comments

  • Jeffery on How Can We Look So Good But Feel So Bad with CFS & Fibromyalgia?
  • Irakli Khvedelidze on How Can We Look So Good But Feel So Bad with CFS & Fibromyalgia?
  • Wayne Johnson on How Can We Look So Good But Feel So Bad with CFS & Fibromyalgia?
  • Chan KWAN on How Can We Look So Good But Feel So Bad with CFS & Fibromyalgia?
  • Ernesto Martinez on How Can We Look So Good But Feel So Bad with CFS & Fibromyalgia?
  • YUH on How Can We Look So Good But Feel So Bad with CFS & Fibromyalgia?
  • Analicia Burnett on How Can We Look So Good But Feel So Bad with CFS & Fibromyalgia?

Secondary Sidebar

Sub Topics

  • Fibromyalgia Awareness
  • Fibromyalgia Research
  • Fibromyalgia Symptoms
  • Fibromyalgia Treatments

Copyright © 2023 · FightingFatigue.org